Skip to main content
SpringerLink
Log in

Cost of Epilepsy

A Systematic Review

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

The objective of this review was to overview published cost-of-illness (COI) studies of epilepsy and their methodological approaches. Epilepsy imposes a substantial burden on individuals and society as a whole. The mean prevalence of epilepsy is estimated at 0.52% in Europe, 0.68% in the US, and peaks up to 1.5% in developing countries. Estimation of the economic burden of epilepsy is of pivotal relevance to enable a rational distribution of healthcare resources. This is especially so with the introduction of the newer antiepileptic drugs (AEDs), the marketing of vagal-nerve stimulators and the resurgence of new surgical treatment options, which have the potential to considerably increase the costs of treating epilepsy.

A systematic literature review was performed to identify studies that evaluated direct and indirect costs of epilepsy. Using a standardized assessment form, information on the study design, methodological framework and data sources were extracted from each publication and systematically reported.

We identified 22 studies worldwide on costs of epilepsy. The majority of the studies reflected the costs of epilepsy in Europe (three studies each for the UK and Italy, one study each for Germany, the Netherlands, Switzerland, France and the EU) and the US (four studies), but studies were also available from India (two), Hong Kong, Oman, Burundi, Chile and Mexico. The studies utilized different frameworks to evaluate costs. All used a bottom-up approach; however, only 12 studies (55%) evaluated direct as well as indirect costs. The range for the mean annual direct costs lay between 40 International Dollar purchasing power parities (PPP-$) in rural Burundi and PPP-$4748 (adjusted to 2006 values) in a German epilepsy centre. Recent studies suggest AEDs are becoming the main contributor to direct costs. The mean indirect costs ranged between 12% and 85% of the total annual costs.

Epilepsy is a cost-intensive disorder. A reliable comparison of the different COI studies in epilepsy is not easily feasible, as the evaluated studies show substantial methodological differences with respect to their patient selection criteria, diagnostic stratifications and evaluated costs. Therefore, there is an urgent need for studies that evaluate direct and indirect costs in a standardized fashion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005 Jun; 12 Suppl. 1: 1–27

    Article  PubMed  Google Scholar 

  2. Forsgren I, Beghi E, Ekman M. Cost of epilepsy in Europe. Eur J Neurol 2005 Jun; 12 Suppl. 1: 54–58

    Article  PubMed  Google Scholar 

  3. Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 1991 Jul–Aug; 32 (4): 429–445

    Article  PubMed  CAS  Google Scholar 

  4. Preux PM, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol 2005 Jan; 4 (1): 21–31

    Article  PubMed  Google Scholar 

  5. Begley CE, Annegers JF, Lairson DR, et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994 Nov–Dec; 35 (6): 1230–1243

    Article  PubMed  CAS  Google Scholar 

  6. Jallon P. Prognosis of epilepsies. Montrouge: John Libbey Eurotext, 2003

    Google Scholar 

  7. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000 Feb 3; 342 (5): 314–319

    Article  PubMed  CAS  Google Scholar 

  8. Rosenow F, Luders H. Presurgical evaluation of epilepsy. Brain 2001 Sep; 124 (Pt 9): 1683–1700

    Article  PubMed  CAS  Google Scholar 

  9. Ben-Menachem E, Hellstrom K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology 2002 Sep 24; 59 (6 Suppl. 4): S44–S47

    Article  PubMed  Google Scholar 

  10. Cramer JA, Ben-Menachem E, French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy research 2001 Nov; 47 (1-2): 17–25

    Article  PubMed  CAS  Google Scholar 

  11. Swinkels WA, Kuyk J, van Dyck R, et al. Psychiatric comorbidity in epilepsy. Epilepsy Behav 2005 Aug; 7 (1): 37–50

    Article  PubMed  CAS  Google Scholar 

  12. Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand 2004 Oct; 110 (4): 207–220

    Article  PubMed  CAS  Google Scholar 

  13. Baker GA. The psychosocial burden of epilepsy. Epilepsia 2002; 43 Suppl. 6: 26–30

    Article  PubMed  Google Scholar 

  14. Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a UK community study. Epilepsia 1996 Feb; 37 (2): 148–161

    Article  PubMed  CAS  Google Scholar 

  15. Jacoby A. Stigma, epilepsy, and quality of life. Epilepsy Behav 2002 Dec; 3 (6S2): 10–20

    Article  PubMed  Google Scholar 

  16. Smeets VM, van Lierop BA, Vanhoutvin JP, et al. Epilepsy and employment: literature review. Epilepsy Behav 2007 May; 10 (3): 354–362

    Article  PubMed  Google Scholar 

  17. UK NHS Centre for Reviews and Dissemination [online]. Available from URL: http://www.york.ac.uk/inst/crd [Accessed 2007 Jul 20]

  18. German Institute of Medical Documentation and Information [online]. Available from URL: http://www.dimdi.de [Accessed 2007 Jul 20]

  19. Begley CE, Annegers JF, Lairson DR, et al. Estimating the cost of epilepsy. Epilepsia 1999; 40 Suppl. 8: 8–13

    Article  PubMed  Google Scholar 

  20. Kotsopoulos IA, Evers SM, Ament AJ, et al. Estimating the costs of epilepsy: an international comparison of epilepsy cost studies. Epilepsia 2001 May; 42 (5): 634–640

    Article  PubMed  CAS  Google Scholar 

  21. Brunetti M, Pagano E, Garattini L. The economic cost of epilepsy: a review. Ital J Neurol Sci 1998 Apr; 19 (2): 116–119

    Article  PubMed  CAS  Google Scholar 

  22. Federal Reserve Bank of Cleveland [online]. Available from URL: http://www.clevelandfed.org [Accessed 2007 Nov 15]

  23. Drummond M. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 2005

    Google Scholar 

  24. Millennium Development Goals Indicators [online]. Available from URL: http://mdgs.un.org/unsd/mdg [Accessed 2007 Nov 15]

  25. Cockerell OC, Hart YM, Sander JW, et al. The cost of epilepsy in the United Kingdom: an estimation based on the results of two population-based studies. Epilepsy Res 1994 Jul; 18 (3): 249–260

    Article  PubMed  CAS  Google Scholar 

  26. Jacoby A, Buck D, Baker G, et al. Uptake and costs of care for epilepsy: findings from a UK regional study. Epilepsia 1998 Jul; 39 (7): 776–786

    Article  PubMed  CAS  Google Scholar 

  27. Swingler RJ, Davidson DL, Roberts RC, et al. The cost of epilepsy in patients attending a specialist epilepsy service. Seizure 1994 Jun; 3 (2): 115–120

    Article  PubMed  CAS  Google Scholar 

  28. Beghi E, Garattini L, Ricci E, et al. Direct cost of medical management of epilepsy among adults in Italy: a prospective cost-of-illness study (EPICOS). Epilepsia 2004 Feb; 45 (2): 171–178

    Article  PubMed  Google Scholar 

  29. Berto P, Tinuper P, Viaggi S. Cost-of-illness of epilepsy in Italy: data from a multicentre observational study (Episcreen). Pharmacoeconomics 2000; 17 (2): 197–208

    Article  PubMed  CAS  Google Scholar 

  30. Tetto A, Manzoni P, Millul A, et al. The costs of epilepsy in Italy: a prospective cost-of-illness study in referral patients with disease of different severity. Epilepsy Res 2002 Feb; 48 (3): 207–216

    Article  PubMed  CAS  Google Scholar 

  31. Hamer HM, Spottke A, Aletsee C, et al. Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006 Dec; 47 (12): 2165–2172

    Article  PubMed  Google Scholar 

  32. Kotsopoulos I A, Evers SM, Ament AJ, et al. The costs of epilepsy in three different populations of patients with epilepsy. Epilepsy Res 2003 May; 54 (2-3): 131–140

    Article  PubMed  Google Scholar 

  33. Gessner U, Sagmeister M, Horisberger B. The costs of epilepsy in Switzerland. Int J Health Sci 1993; 4 (3): 121–128

    Google Scholar 

  34. De Zelicourt M, Buteau L, Fagnani F, et al. The contributing factors to medical cost of epilepsy: an estimation based on a French prospective cohort study of patients with newly diagnosed epileptic seizures (the CAROLE study). Active Coordination of the Longitudinal Observational Network in Epilepsy. Seizure 2000 Mar; 9 (2): 88–95

    Article  PubMed  Google Scholar 

  35. Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000 Mar; 41 (3): 342–351

    Article  PubMed  CAS  Google Scholar 

  36. Halpern M, Rentz A, Murray M. Cost of illness of epilepsy in the US: comparison of patient-based and population-based estimates. Neuroepidemiology 2000 Mar–Apr; 19 (2): 87–99

    Article  PubMed  CAS  Google Scholar 

  37. Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996 Mar; 23 (2): 139–148

    Article  PubMed  CAS  Google Scholar 

  38. Krishnan A, Sahariah SU, Kapoor SK. Cost of epilepsy in patients attending a secondary-level hospital in India. Epilepsia 2004 Mar; 45 (3): 289–291

    Article  PubMed  Google Scholar 

  39. Thomas SV, Sarma PS, Alexander M, et al. Economic burden of epilepsy in India. Epilepsia 2001 Aug; 42 (8): 1052–1060

    Article  PubMed  CAS  Google Scholar 

  40. Mak W, Fong JK, Cheung RT, et al. Cost of epilepsy in Hong Kong: experience from a regional hospital. Seizure 1999 Dec; 8 (8): 456–464

    Article  PubMed  CAS  Google Scholar 

  41. Al-Zakwani I, Hanssens Y, Deleu D, et al. Annual direct medical cost and contributing factors to total cost of epilepsy in Oman. Seizure 2003 Dec; 12 (8): 555–560

    Article  PubMed  Google Scholar 

  42. Nsengiyumva G, Dmet-Cabanac M, Nzisabira L, et al. Economic evaluation of epilepsy in Kiremba (Burundi): a case-control study. Epilepsia 2004 Jun; 45 (6): 673–677

    Article  PubMed  Google Scholar 

  43. Mesa T, Mesa JT, Guarda J, et al. The direct costs of epilepsy in a Chilean population [in Spanish]. Rev Neurol 2007 Jun 16–30; 44 (12): 710–714

    PubMed  CAS  Google Scholar 

  44. Garcia-Contreras F, Constantino-Casas P, Castro-Rios A, et al. Direct medical costs for partial refractory epilepsy in Mexico. Arch Med Res 2006 Apr; 37 (3): 376–383

    Article  PubMed  Google Scholar 

  45. WHO. Epilepsy: historical overview [fact sheet no. 168]. Geneva: WHO, 2001

    Google Scholar 

  46. Meinardi H, Scott RA, Reis R, et al. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia 2001 Jan; 42 (1): 136–149

    Article  PubMed  CAS  Google Scholar 

  47. Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing countries: where do we go from here? Bull World Health Organ 2001; 79 (4): 344–351

    PubMed  CAS  Google Scholar 

  48. WHO. Epilepsy: social consequences and economic aspects [fact sheet no. 166]. Geneva: WHO, 2001

    Google Scholar 

  49. International Monetary Fund. World Economic Outlook Database, April 2007 edition [online]. Available from URL: http://www.imf.org/external/pubs/ft/weo/2007/01/data/index.aspx [Accessed 2007 Jul 20]

  50. Koopmanschap MA, Rutten FF, van Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995 Jun; 14 (2): 171–189

    Article  PubMed  CAS  Google Scholar 

  51. Drummond MF. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005

    Google Scholar 

  52. Goeree R, O’Brien BJ, Blackhouse G, et al. The valuation of productivity costs due to premature mortality: a comparison of the human-capital and friction-cost methods for schizophrenia. Can J Psychiatry 1999 Jun; 44 (5): 455–463

    PubMed  CAS  Google Scholar 

  53. Graf von der Schulenburg J-M, Hoffmann C. Review of European guidelines for economic evaluation of medical technologies and pharmaceuticals. HEPAC 2000; 1: 2–8

    Article  Google Scholar 

  54. Tsiropoulos I, Gichangi A, Andersen M, et al. Trends in utilization of antiepileptic drugs in Denmark. Acta Neurol Scand 2006 Jun; 113 (6): 405–411

    Article  PubMed  CAS  Google Scholar 

  55. Andermann F, Duh MS, Gosselin A, et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007 Mar; 48 (3): 464–469

    Article  PubMed  CAS  Google Scholar 

  56. Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 2007 May; 6 (5): 465–468

    Article  PubMed  Google Scholar 

  57. Kramer G, Steinhoff BJ, Feucht M, et al. Experience with generic drugs in epilepsy patients: an electronic survey of members of the German, Austrian and Swiss branches of the ILAE. Epilepsia 2007 Mar; 48 (3): 609–611

    Article  PubMed  Google Scholar 

  58. Ekman M, Forsgren L. Economic evidence in epilepsy: a review. Eur J Health Econ 2004 Oct; 5 Suppl. 1: S36–S42

    Article  PubMed  Google Scholar 

  59. Langfitt JT. Cost evaluations in epilepsy: an update. Epilepsia 2000; 41 Suppl. 2: S62–S68

    Article  PubMed  Google Scholar 

  60. Begley CE, Beghi E, Beran RG, et al. ILAE Commission on the Burden of Epilepsy, Subcommission on the Economic Burden of Epilepsy: final report 1998–2001. Epilepsia 2002 Jun; 43 (6): 668–673

    Article  PubMed  Google Scholar 

  61. Schöffski O, Schulenburg J. Gesundheitsökonomische Evaluationen. 3, vollständig überarb. Aufl. ed. Berlin: Springer, 2007

    Google Scholar 

  62. Begley CE, Annegers JF, Lairson DR, et al. Methodological issues in estimating the cost of epilepsy. Epilepsy Res 1999 Jan; 33 (1): 39–55

    Article  PubMed  CAS  Google Scholar 

  63. Frost FJ, Hurley JS, Petersen HV, et al. A comparison of two methods for estimating the health care costs of epilepsy. Epilepsia 2000 Aug; 41 (8): 1020–1026

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Neurology, Philipps-University, Rudolf-Bultmann-Str. 8, Marburg, 35039, Germany

    Adam Strzelczyk, Jens Peter Reese,  Richard Dodel & Hajo M. Hamer

Authors
  1. Adam Strzelczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jens Peter Reese
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard Dodel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hajo M. Hamer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Dodel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Strzelczyk, A., Reese, J.P., Dodel, R. et al. Cost of Epilepsy. Pharmacoeconomics 26, 463–476 (2008). https://doi.org/10.2165/00019053-200826060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200826060-00002

Keywords

Search

Navigation